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ProteostasisPolyunsaturated fatty acids are susceptible to peroxidation and they yield various degradation products, includ-
ing themainα,β-unsaturated hydroxyalkenal, 4-hydroxy-2,3-trans-nonenal (HNE) in oxidative stress. Due to its
high reactivity, HNE interacts with various macromolecules of the cell, and this general toxicity clearly contrib-
utes to a wide variety of pathological conditions. In addition, growing evidence suggests a more speciﬁc function
of HNE in electrophilic signaling as a secondmessenger of oxidative/electrophilic stress. It can induce antioxidant
defense mechanisms to restrain its own production and to enhance the cellular protection against oxidative
stress. Moreover, HNE-mediated signaling can largely inﬂuence the fate of the cell throughmodulatingmajor cel-
lular processes, such as autophagy, proliferation and apoptosis. This review focuses on themolecularmechanisms
underlying the signaling and regulatory functions of HNE. The role of HNE in the pathophysiology of cancer,
cardiovascular and neurodegenerative diseases is also discussed.
© 2015 Elsevier B.V. All rights reserved.1. Synthesis and breakdown of HNE
4-Hydroxy-2,3-trans-nonenal (4-hydroxynonenal, HNE) is an α,β-
unsaturated hydroxyalkenal. The molecule is highly reactive due to its
three functional groups: an aldehyde, a double bond (alkene) between
carbon C2 and C3, and a secondary alcohol at carbon C4 (Fig. 1). Carbon
C1 and C3 are electrophilic sites and carbon C1 is also a redox center.
The compound was ﬁrst described in autooxidized polyunsaturated
fatty acids (PUFAs) and triglycerides [1]. The ﬁrst report on the forma-
tion of HNE in a biological system was published Benedetti et al. in
Biochim. Biophys. Acta in 1980 [2]. This pioneer work investigated the
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iv.hu (G. Bánhegyi).microsomes, including the defective activity of glucose-6-phosphatase,
and identiﬁed HNE as the underlying toxic intermediate.
1.1. HNE formation
Lipid peroxidation is a general term, which refers to different mech-
anisms and can be classiﬁed as enzymatic, non-enzymatic non-radical
and non-enzymatic free-radical mediated peroxidation [3]. Free-
radical non-enzymatic peroxidation of PUFAs is the dominant pathway
in oxidative stress induced by radiation, heat, free radicals, xenobiotics,
metal ions or reactive oxygen or nitrogen species (ROS or RNS). Hydrox-
yl radical (OH·), themost powerful initiator of lipid peroxidation can be
generated from hydrogen peroxide via the Fenton– and Haber–Weiss
reactions, in the presence of free iron or copper ions. Lipid peroxidation
can be initiated by a hydroxyl-radical-mediated removal of anH• radical
from a lipid (LH), which yields a lipid radical (L•). In the propagation
phase, L• reacts with oxygen and forms a lipoperoxyl radical (LOO•).
Lipoperoxyl radical in turn reacts with another PUFA to yield a new L•
and a lipid hydroperoxyde (LOOH). Thus, one hydroxyl radical can gen-
erate a high number of lipid hydroperoxydes until the chain reaction is
terminated by a chain-breaking antioxidant (e.g. tocopherol).
Lipid hydroperoxydes are regarded as primary products of lipid per-
oxidation (Fig. 2). However, these compounds are unstable: they can be
Fig. 1. Chemical structure of 4-hydroxy-2,3-trans-nonenal (HNE). Circles indicate the
reactive groups of the molecule; the arrow shows the site of nucleophilic attack.
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decomposed to secondary products. Alkoxyl radicals are especially
prone to β-scission, which results in the formation of short-chain prod-
ucts, including HNE (Fig. 2). Among the end products of lipid peroxida-
tion other reactive aldehydes, such asmalondialdehyde (MDA) are also
present; for more detailed description of the biosynthetic pathways we
refer to recent excellent reviews [4,5].
The secondary products of lipid peroxidation are reactive, yet rela-
tively stable compounds, they can travel remarkable distances from
the site of synthesis. HNE, for instance can reach well measurable
concentrations in the tissues and in the blood, thus it can be regarded
as a biomarker of the oxidative stress. Its physiological concentration
is in the submicromolar range (b0.1 μM), while in oxidative stress,
even micromolar levels can be observed [6].1.2. Biotransformation of HNE
In situ lipid peroxidation is not the only source of HNE as it can also
be taken up with the food [7]. Thus, HNE is both a xeno- and an endobi-
otic substrate for biotransformation. Themetabolism of HNE (and other
secondary lipid peroxidation products) is rapid and effective, involving
all phases of biotransformation. Since the molecule already possesses
functional groups suitable for conjugation, the phases I and II of
biotransformation can be reversed. It should be noted that the relative
contribution of various pathways to HNE biotransformation markedly
differs in different species and tissues (see e.g.[8]), which can be in the
background of variable toxicity of HNE.Fig. 2. Outline of HNE metabolism. HNE is generated as secondary product of lipid perox-
idation. It can be detoxiﬁed by various reactions of biotransformation; alternatively, it can
form macromolecular adducts.1.2.1. Phase I reactions
The aldehyde group is a substrate for oxidoreductases, and it can be
reduced to an alcoholic hydroxyl or oxidized to a carboxylic group. The
participating enzymes are aldose reductase and aldehyde dehydroge-
nase; they form 1,4-dihydroxynonene and 4-hydroxynonenoate,
respectively [9,10]. The latter product can undergo a consecutive β-
oxidation. Several cytochrome P450 isozymes have been also shown
to catalyze both the oxidation [11] and the reduction [12] of the alde-
hyde group. Cytochome P450s of the CYP4A family are also involved
in the oxidativemetabolismof HNE, by catalyzing theω- andω-1 oxida-
tion of 4-hydroxynonenoate [13,14]. Ketogenic diet upregulatesω- and
ω-1 hydroxyation of 4-hydroxynonenoate in rat liver via the induction
of CYP4A isozymes [14]. The hydroxyl group of carbon C4 and the
double bond between C2 and C3 are also subjects of oxidation or reduc-
tion, respectively.
1.2.2. Phase II reactions
The carbon-carbon double bond of HNE reacts with nucleophilic
thiol groups, including that of the tripeptide glutathione (GSH). Michael
addition leads to the formation of GSH conjugates. This spontaneous re-
action can be highly accelerated by glutathione-S-transferases. The con-
jugation reaction is present in most cells and tissues.
The glutathione conjugation can be followed by oxidoreductions
described above; and thence the glutathione conjugates of 1,4-
dihydroxynonane and 4-hydroxynonanate are formed. Aldose reduc-
tase has a low micromolar KM towards the glutathione conjugate of
HNE, thus this metabolic pathways seems to be dominant in vivo [15].
It should be noted that the glutathione conjugates of HNE are not in-
active product, but potential signal molecules. Mitogenic effect of HNE
has been reported to bemediated by the glutathione conjugate reduced
by aldose reductase in rat aortic smooth muscle cells [16]. These
compounds were also shown to mediate the inﬂammatory effect of
oxidative or glucotoxic stress in adipocytes [17,18]. Inhibition of aldose
reductase prevented systemic inﬂammation and cardiomyopathy upon
endotoxin treatment [19].
The oxidized acidic derivatives can be further metabolized by cyto-
chrome P4504A, yieldingω-hydroxylated metabolites. Themercapturic
acid derivatives of these products are present in the urine and can serve
as biomarkers of in vivo lipid peroxidation (for a review see [20]). Glu-
tathione andmercapturic acid conjugates of HNE, 1,4-dihydroxynonane
and 4-hydroxynonanate are secreted also into the bile.
Cysteine can be also a conjugation partner for HNE. In a recent study
increased extracellular formation of HNE-cysteine conjugate was ob-
served in colon cells with a mutation of the adenomatous polyposis
coli gene; the reaction – together with the upregulation of aldehyde de-
hydrogenases, glutathione transferase and cystine transporter – confers
higher resistance towards HNE in mutant cells [21].
1.2.3. Phase III reactions
MRP1 and MRP2 multidrug resistance proteins have been shown to
transport glutathione conjugates of HNE and to protect the cell from
HNE toxicity [22,23]. Another ATP dependent, but non-ABC transporter,
RLIP76 (Ral-interacting GTPase activating protein, also known as Ral-
binding protein 1) has high transport activity towards glutathione
conjugates of HNE; this protein accounts for the majority of the trans-
port [24,25]. Indeed, overexpression of RLIP76 abolished the mitogenic
effects of HNE and its glutathione conjugates observed in rat aortic
smoothmuscle cells, while its downregulation promoted themitogenic
effects [14].
1.3. Adduct formation
HNE accumulation and toxicity are counteracted by an efﬁcient and
rapid biotransformation. Yet, in spite of these protective efforts, HNE is
present in the cells at measurable concentrations, and gives rise to un-
desired events. HNE is able to react readily with various cellular
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cleophilic thiol or amino groups [6,26]. The C2-C3 double bond is re-
sponsible for the Michael addition of thiol or amino compounds at the
C3 carbon (Fig. 3). The C1 aldehyde group can react with primary
amines and formof Schiff bases.While Schiff base formation is relatively
slow and reversible, Michael adducts are stable, thus the formation of
the latter is preferred in vivo. The cysteinyl, lysyl and histidyl residues
of proteins are the main targets of Michael addition. HNE can also
react with lipids containing amino groups (e.g. phosphatidyl ethanol-
amine, phosphatidyl serine, sphingosine) andwith nucleic acids, prefer-
ably with the guanin base of DNA (Fig. 3). HNE-DNA adduct formation
and the consequent mutagenicity occur in two independent pathways:
i, direct interaction of HNE with two nitrogen atoms in guanine
moieties,which yields four isomeric propano adducts [27], and ii, oxida-
tion of HNE to 2,3-epoxy-4-hydroxy-nonanal [28] and a consecutive
formation of exocyclic etheno adducts of guanine, adenine or cytosine
moieties [29,30]. The different genotoxicity of HNE in various organs –
beside the differences in tissue level of HNE and intensity of DNA repair
mechanisms – can be attributed to the tissue- or cell-speciﬁc predomi-
nance of one of the two pathways, e.g. the latter one is dominant in
hepatocytes [31].
Protein-HNE adduct formation can lead to alterations in the normal
functioning and modiﬁed activity of various proteins (for reviews, see
[32–34]. Because of its double reactivity (Michael addition and Schiff
bases)), HNE can contribute to protein cross-linking and induce a
carbonyl stress.2. HNE in signaling
Only a few plausible effects can be outlined among the confusingly
pleiotropic actions of HNE in cell signaling. Antioxidant, heat shock
and ER stress responses are activated by HNE and these responses can
be integrated into a uniﬁed scheme. The three adaptive pathways
serve not only the disposal of HNE and the prevention of its toxic effects,
but also the negative regulation of proteostasis and stimulation of pro-
tein folding. These latter mechanisms help the cell to enter the lists
against adduct formation and misfolding.Fig. 3. Protein and DNA adducts of HNE. Reaction between C1 aldehyde group and primary am
cysteinyl, lysyl and histidyl residues of proteins yielding Michael adducts (B). HNE oxidized to
form propano adducts with guanine bases of DNA (D).2.1. The Keap1–Nrf2–ARE pathway
Exogenously added HNE has been shown to interact with practically
any signalingpathways in cells (for an extensive list of these interactions
see [35]), leading to pathological responses. These effects are due to the
covalent interactions of HNE with key proteins of signal transduction
pathways; there are no experimental evidences for classic, ligand-type
interactions. Themain target of HNE as amajor endogenous electrophil-
ic compound is the Keap1 (Kelch ECH associating protein 1)–Nrf2
(nuclear factor erythroid 2-related factor 2)–ARE (antioxidant response
element) pathway (Fig. 4). This pathway senses prooxidant effects and
organizes the cellular response against oxidant or electrophile stress.
The extremely cysteine-rich Keap1 under stress-free conditions binds
Nrf2 and directs it towards ubiquitylation and proteasomal degradation.
Cysteine residues of Keap1 are sensitive to electrophilic attacks; while
electrophiles in high concentrations form adducts almost completely
with cysteinyl thiols, in low concentrations they react with a speciﬁc
subset of thiols [36,37]. It has been reported that Keap1 directly recog-
nizes alkenals (including HNE), NO and Zn2+ by three distinct sensors
composed by cysteines and basic amino acids [38]. Phylogenetic analy-
ses showed that the alkenal sensor is the most ancient one.
Independently from the nature of the electrophilic stimuli, it seems
that the downstream events are the same; adduct formation or oxida-
tion of cysteine residues of Keap1 compromises its potential to recruit
the ubiquitin ligase complex, thus Nrf2 can accumulate. The stabilized
and accumulated Nrf2, a basic leucine zipper transcription factor, trans-
locates to the nucleus, binds to AREs and regulates target genes. The
proteins coded by these genes can be divided into different functional
groups.
NADPH generation is controlled by Nrf2 via glucose-6-phosphate
dehydrogenase, phosphogluconate dehydrogenase, malic enzyme 1
and isocitrate dehydrogenase 1 expression. NADPH is used by the
glutathione and thioredoxin systems as an electron donor. The
expression of enzymes of glutathione synthesis, regeneration and utili-
zation (e.g. glutamate–cysteine ligase, glutathione reductase,
glutathione-S-transferases and glutathione peroxidase) are also
regulated by Nrf2, similarly to those of the thioredoxin system
(thioredoxin 1, thioredoxin reductase 1 and peroxiredoxin 1).ines results in Schiff base formation (A). The C2–C3 double bond of HNE can react with
an epoxide reacts with different bases in DNA forming etheno adducts (C). HNE can also
Fig. 4. The Keap1–Nrf2–ARE pathway of electrophilic signaling. Under basal conditions, Keap1 binds Nrf2 and promotes its ubiquitylation by Cul3 ubiquitin ligase. Upon elec-
trophilic exposure, electrophiles (e.g. HNE) react with thiol groups of Keap1, which results in the dissociation of Cul3 (Cul3 dissociation model) or in a partial detachment of
Nrf2 (hinge and latch model). In both cases Nrf2 escapes ubiquitylation, accumulates, translocates into the nucleus, binds to antioxidant response elements (AREs) and in-
creases the expression of Nrf2 target genes. Phosphorylation of Nrf2 by protein kinases (including PKC, MAPKs and the ER stress kinase PERK) also promotes the dissociation
of the Keap1–Nrf2 complex.
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oxygenase-1, UDP-glucuronosyltransferases and multidrug-resistance
associated proteins completes the antioxidant effects [39]. The ﬁnal out-
comes of the signaling pathway are a reinforced antioxidant defense
and a redox shift towards the more reducing conditions.
Beside this simpliﬁedmechanism, Keap1 and Nrf2 are also targets of
protein kinases and phosphatases; many of them are also redox-
sensitive. Recent ﬁndings show that the PI3K pathway activates Nrf2
[40]. The complexity of the upstream regulation of Nrf2 is evidenced
by its huge interactome [41,42].
Recent observations suggest that the Keap1–Nrf2–ARE pathway is
much more than a signaling system for electrophilic or oxidative stress;
it might have a crucial function in the healthy cells too. Some of its
signals (e.g. NO) are produced as a second messenger upon various
physiological situations. Moreover, ARE-responsive proteins include
NADPH generating enzymes, which have prominent role in the interme-
diarymetabolism. These considerations raise the possibility that Keap1–
Nrf2 signaling plays a more general role in redox signaling [36,43].2.2. Endoplasmic reticulum stress — the unfolded protein response
Accumulation of unfolded or misfolded proteins in the ER lumen re-
sults in ER stress, which provokes an adaptation mechanism called the
unfolded protein response (UPR). The UPR moderates protein transla-
tion and induces ER chaperones to restore protein folding and luminal
homeostasis, i.e. the normal macromolecular crowding, redox condi-
tions and Ca2+ concentration [44]. HNE and its effect were ﬁrstly de-
scribed in rat liver microsomes derived from the ER [2,45–47]; thus, it
is not surprising that HNE can interact with the machinery of protein
folding, leading to ER stress. Indeed, it has been reported thatHNE reacts
with the key players of ER folding, protein disulﬁde isomerase [48,49],
and Grp78 [48,50]. The ER stress sensor PERK kinase was activatedupon HNE exposure in rat aortic smooth muscle cells [48]. Exogenous
HNE provokes ER stress by a mechanism independent from ROS forma-
tion or glutathione depletion in endothelial cells [51]. The role of ROS as
a possible mediator of HNE-dependent ER stress was also excluded by
another study performed in PC12 cells [52].
An important crosstalk between the UPR and the Nrf2 pathway has
also been described. It was observed that Nrf2 is a substrate for PERK
ER kinase, which is activated in ER stress [53]. Upon phosphorylation
the interaction between Keap1 and Nrf2 is weaker and the complex
dissociates. Thus, HNE-provoked ER stress ampliﬁes the electrophilic
signaling pathway. Interestingly, in de-differentiated cells, a constitu-
tive (ER stress independent) PERK-Nrf2 signaling was observed, which
protects de-differentiated cells from chemotherapy by increased anti-
oxidant defense and drug efﬂux [54].2.3. The heat shock response
Heat shock response is an adaptive mechanism, which confers resis-
tance to various stress conditions caused by heat, electrophiles, xenobi-
otics etc. by initiating a transcriptional program primarily regulated by
heat shock factor 1 (HSF1). HSF1 upon stress conditions stimulates the
expression of various heat shock proteins (HSPs). Similarly to ER chap-
erones, their cytosolic counterparts HSP70 and HSP90 are also candi-
dates for HNE-dependent modiﬁcations [55,56]. Although the exact
mechanism is unknown, it can be supposed that modiﬁed HSPs lose
their repressor functions on HSF1 activation. Thus, HNE can induce
heat shock response by an indirect mechanism: binding to HSP70 re-
sults in the release of HSF1 from an inactive cytosolic complex and in
the increased transcription of the genes of heat shock proteins [33]. In
accordance with this mechanism, HSF1 via HSP70 induction prevents
the cell from HNE-induced apoptosis [57], while the HSP inhibitor
geldanamycin sensitizes the cells towards HNE-dependent cell death
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protein conformational diseases; many of the candidate compounds
are electrophiles and activators of the Nrf2 pathway too [59,60].
2.4. HNE signaling and proteostasis
Beside redox/antioxidant regulation, the Keap1–Nrf2–ARE pathway
is an important regulator of proteostasis. The autophagy substrate p62
interacts with the Nrf2-binding site on Keap1, consequently deﬁcient
autophagy results in the accumulation of p62, stabilization of Nrf2 and
transcriptional activation of Nrf2 target genes [61]. On the other hand,
p62 has been shown to be an ARE-responsive gene product [62], thus
p62 creates a positive feedback loop in Nrf2 signaling. Nrf2 dependent
mechanisms are also present in the crosstalk between proteasomal
and autophagic proteolysis. Increased autophagy was observed in mu-
tant mice with proteasomal dysfunction, which was stimulated by the
Keap1–Nrf2 pathway [63]. Nrf2 activation is required for the increased
level of the proteasomal regulator Pa28αβ and for maximal proteolytic
capacity of proteasomes [64]. Thus, electrophiles and other Nrf2 activa-
tors can regulate stress-induced proteasomal activity and removal of
damaged/misfolded proteins [65]. Since HNE-dependent ER stress and
the consequent activation of UPR are well documented (see above),
the activation of ER associated degradation (ERAD) – a proteasomal
pathway – and ER stress dependent autophagy is not surprising [65].
Moreover, HNE can also directly interact with the apparatus of transla-
tion; e.g. adduct formationwith eukaryotic elongation factor 2 results in
declined protein synthesis [66].
3. HNE in cell life and death decisions
As a potent protein-, lipid- and DNA-damaging agent, which triggers
ROS generation and directly depletes the antioxidant capacity of the
cells, HNE can be expected to cause profound changes in fundamental
cellular processes. Similarly to other insults, excessive lipid peroxidation
or HNE treatment is alsomanaged by the cells in threeways. The prima-
ry response aims adaptation by eliminating the damagedmolecules and
preventing any further aggravation and more serious consequences.
Cell cycle arrest (quiescence or senescence) and activation of autophagy
ﬁt nicely into this strategy. A short-lasting mild or moderate challenge
(i.e. low concentrations of HNE) can be survived this way. If the com-
pensatory attempts fail and the cellular intactness is in jeopardy, pro-
grammed cell death still provides a chance to maintain the integrity of
the tissue and of the whole organism. However, the energy-requiring,
active process of apoptosis can be accomplished only if the cell has
enough time and still possesses its basicmetabolic features.More severe
conditions, when the cell is quickly paralyzed by an overwhelming de-
struction (i.e. high concentrations of HNE), lead to necrosis [67] and a
more pronounced and expanded tissue loss usually combined with in-
ﬂammation. Although an increase in the level of HNE clearly reduces
the chance of adaptation in favor of apoptosis or necrosis, the exact
HNE doses determining one or the other cell response cannot be uni-
formly deﬁned as they vary according to the cell types, duration and
several environmental factors.
Lipid peroxidation is accelerated in oxidative stress and it is a source
of further ROS generation, itself. Therefore, the effects of HNE on au-
tophagy, cell proliferation and apoptosis are often indirect and hard to
distinguish from those of other ROS- and stress-activated signaling
mechanisms. This chapter focuses on the observations that convincingly
suggest a direct interaction of HNE with the key components of these
cellular processes.
3.1. Effect of HNE on autophagy
Besides proteasome-dependent proteolysis, autophagy is a major
physiologicalmechanism to degrade intracellular proteins in eukaryotic
cells. Autophagy plays an important role in differentiation and normalgrowth control, and its enhancement is essential for the survival during
starvation. Macro- and microautophagy sequestrate complete regions
of the cytosol including organelles, while in chaperone-mediated
autophagy contributes to the cellular protein quality-control as it selec-
tively removes damaged cytosolic proteins one by one [68]. The pro-
teins sequestrated by autophagy are degraded in the lysosomes [69],
and hence turn into valuable endogenous nutrient sources. Accordingly,
the process is stimulated in energy deﬁcient states by AMP-activated
protein kinase and inhibited during the wealth of nutrients by (insu-
lin)-Akt-mTOR signaling [70]. The ER can also generate signals to
enhance autophagy, in accordance to its function as a nutrient sensor
in the cells [71]. There is ample evidence that accumulation of ROS-
mediated damages in macromolecules and organelles plays a central
role in aging. Elimination of damaged cellular components through
autophagy is amajor determinant of longevity, and the repeatedly dem-
onstrated anti-aging effect of caloric restriction can be at least partly
attributed to an enhanced autophagic activity [72,73].
The role of chaperone-mediated autophagy in the removal of HNE-
modiﬁed proteinswas demonstrated in transgenicmice overexpressing
LAMP2A receptor. The livers of these animals accumulate fewer dam-
aged proteins compared to age-matched wild-type controls due to an
enhanced chaperone-mediated autophagy [74]. Activation of autopha-
gy in oxidative stress can be considered as an antioxidant defensemech-
anism concerning the protective role it plays by eliminating damaged,
dysfunctional proteins and organelles [75,76]. Stimulation of autophagy
seems to be a pro-survival mechanism in cells undergoing excessive
lipid peroxidation. HNE and other lipid peroxidation-derived aldehydes
caused a remarkable increase in the number of autophagosomes in cul-
tured rat aortic smooth-muscle cells. Enhanced autophagy largely con-
tributed to the elimination of damaged proteins, and also prevented
cell death [77]. The ER as the organelle speciﬁed to protein synthesis,
maturation and quality control [78] is also involved in HNE-induced
autophagy. Luminal accumulation of damaged polypeptides is the key
trigger to the ER stress, which in turn is an important source of signals
stimulating autophagy [79]. The contribution of the ER stress to HNE-
enhanced autophagy was indeed demonstrated in rat aortic smooth-
muscle cells [48]. Sublethal concentration of HNE was also shown to
stimulate protective autophagy in differentiated SH-SY5Y neuroblasto-
ma cells. Although caspase-3 activation was also observed in the HNE-
treated cells, apoptotic cell death intensiﬁed only when autophagy
had been attenuated through inhibition of glycolysis [80].
A complex and differential regulation of autophagy by HNE during
myocardial ischemia and reperfusion has been suggested by a recent
study, in which the effect of endogenous HNE was attenuated by over-
expression of aldehyde dehydrogenase 2 (ALDH2). ALDH2, one of the
major enzymes involved in neutralization of HNE reduced the tissue
damage in both ischemia and reperfusion; however its protective effect
was due to promotion or inhibition of autophagy in the two phases, re-
spectively. The results indicate that AMP-activated protein kinase and
Akt-mTOR signaling is compromised by HNE through interference
with upstream regulators, such as LKB1 and PTEN [81]. It can be also
concluded that HNE-induced autophagy, albeit protective against apo-
ptosis, has its own deleterious consequences especially in themyocardi-
um. Suppression of HNE-stimulated autophagy in ALDH2-transfected
mice has also been reported to ameliorate doxorubicin-induced myo-
cardial dysfunction [82].
Intracellular proteins severely damaged by MDA and HNE may be-
come undegradable due to their aberrant covalent modiﬁcations and
their deposition is potentially cytotoxic. Lipofuscin of human retinal pig-
ment epitheliumwas shown to contain injured mitochondrial proteins,
which indicates the role of autophagy in the formation of such granules
[83]. Further analysis revealed that MDA and HNE interfere with lyso-
somal protease activities in these cells both directly and through modi-
ﬁcations of their substrate peptides [84]. The lysosomal dysfunction
results in increased lipofuscinogenesis and reduced autophagy activity
in vitro [85].
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Protein (Ser/Thr) phosphorylations catalyzed by various cyclin:cyclin-
dependent kinase (CDK) dimers are key events at the checkpoints in the
eukaryotic cell cycle. For instance, the restrictionpoint is passedwhen ret-
inoblastoma protein (pRb) is hyperphosphorylated by cyclin:CDK dimers
accumulating as a result of mitogenic gene expression. The concomitant
liberation (and activation) of members of the E2F family of transcription
factors prepare the now committed cell to enter the S phase (DNA repli-
cation) [86]. CDK activities are controlled by positively andnegatively act-
ing phosphorylations and can be halted by the association of CDK
inhibitors, such as p21 or p16 [87]. The latter mechanism contributes to
the anti-proliferative action of p53 family transcription factors [88],
which in turn is activated by various stress conditions, oncogenic insult
and severe DNA-damage [89].
3.2.1. Anti-proliferative effects
An inverse relationship was found between cell proliferation and
lipid peroxidation in various cell types, i.e. it is generally observed that
rapid proliferation is accompanied by low level of lipid peroxidation in
different tissues including tumors [90]. The phenomenon is at least part-
ly due to low level of peroxidizable fatty acids in intensively proliferat-
ing cells. Enrichment with arachidonic acid renders tumor cells more
susceptible to oxidative stress and to cell cycle arrest through lipid per-
oxidation [91,92]. These ﬁndings shed light on the potential role of HNE
in themodulation of cell cycle control [93]. HNEwas found to reduce the
proliferative capacity of K562 human erythroleukemic and HL-60
human promyelocytic cells [94]. Not only the S phase progression was
inhibited, but a concomitant granulocytic differentiation was also initi-
ated in HNE-treated HL-60 cells [95]. Diversion from proliferation to-
wards differentiation implies the modulation of master regulators of
these processes. Indeed, the expression of proto-oncogen c-myc and c-
myb transcription factors is transiently suppressed in HL-60 cells after
HNE treatment despite unaltered N-ras expression and cAMP levels
[96,97]. A remarkable decrease in the c-myc mRNA level was also
demonstrated in K562 cells after the addition of HNE at low (1–3 μM)
concentration [98]. Further investigation revealed that HNE affects cell
cycle control around the restriction point by modifying the expression
of several genes. It was found to down-regulate D1, D2, and A cyclin ex-
pression [99], as well as to induce p21 and reduce E2F4 expression,
which leads to a lowered pRb phosphorylation [100]. Although p21 is
the major mediator of p53-induced anti-proliferative effects, its ob-
served HNE-dependent induction must involve other, yet-unidentiﬁed
transcription factors in HL-60 cells, which are known to be p53-
deﬁcient [101]. The profound alterations in gene expression shift the
ratio of DNA-bound activating “free” E2F and suppressing E2F–pRb
complexes towards the latter [100]. In line with these observations,
phenotypic transformation and immortalization was found in HLE B-3
and CCL-75 adherent cells upon transfection with HNE-metabolizing
glutathione S-transferase isozymes [102]. The complex pattern of alter-
ations in gene expression included the induction of TGFβ, c-myc, CDK2,
PKCβII and ERK1/2 as well as the down-regulation of p53, p21, p16,
TGFα, and c-jun [102,103]. HNE was also reported to inhibit the prolif-
eration of SK-N-BE neuroblastoma cells through an increased expres-
sion of p53 family proteins and the consequent up-regulation of p21
and down-regulation of cyclin D2, p53 target proteins [104].
3.2.2. Proliferative effects
It is noteworthy that positive effects of HNE on cell proliferation
have also been reported in a few studies. Activation of JNK (but not
ERK) isoforms through direct interaction by HNE leading to an increase
in c-jun (but not c-fos) mRNA levels and a biphasic increase in AP-1
DNA binding was reported in primary human hepatic stellate cells
[105]. In this study, these effects were related to the stimulation of
procollagen type I gene expression and synthesis rather than to the
enhancement of cell proliferation. In fact, HNE has been reported toreduce the platelet-derived growth factor (PDGF)-induced proliferation
through a lowered receptor tyrosine phosphorylation in this cell type
[106]. Stimulation of AP-1 DNA binding activity by HNE was also
found in rat aortic smooth muscle cells. However, in these cells, some-
what controversially, the enhanced cell growthwas attributed to the ac-
tivation of ERK1 and ERK2 and a consequent induction of c-fos and c-jun
protein expression [107]. The anti-proliferative effect of aldehyde dehy-
drogenase 3A1 (ALDH3A1), an effective consumer of HNEwas shown in
primary human corneal epithelial cells and in NCTC-2544 human
keratinocyte cell line. However, this phenomenon might not have
been directly related to the elimination of HNE and was more likely
due to a signalingprotein activity of ALDH3A1 involved inmitosis rather
than its catalytic function [108]. A striking difference between the
effects of HNE on cell proliferation in young and old smooth muscle
cells indicates the age-dependence and complexity of the signaling
involved. Interestingly the increase in ERK signaling activity, cyclin D1
expression and cell growth was more pronounced while the ROS-
mediated cytotoxicity was less obvious in young compared to aged
smooth muscle cells treated with low concentrations 0.1 μM of HNE
for 36 h [109].
3.3. HNE-induced apoptotic cell death
Apoptosis, the major type of programmed cell death is an ATP-
dependent and meticulously regulated process to eliminate disposable
and/or incurable cells. The primary cause of apoptosis in physiological
conditions is the lack of sufﬁcient survival stimuli, but it can be triggered
also by severe stress (e.g. oxidative or organelle stress), DNA-damage,
excessive mitogenic signal (oncogenic insult) or by stimulation of plas-
mamembrane death receptors (e.g. FAS or TNF receptor) by exogenous
ligands (e.g. FAS ligand or TNFα) [110]. Apoptotic caspases, central
executors of the program, can be irreversibly activated upon limited
proteolysis of their zymogens. Cells are protected against premature
or inadequate caspase activation by inhibitors of apoptosis (IAPs),
i.e. proteins blocking the active sites of caspases. Initiator procaspases
(2, 8, 9 and 10) can be auto-activated within certain multiprotein com-
plexes, such as apoptotosome, death inducing signaling complex or
PIDDosome [110]. These are assembled upon the release of cytochrome
c from the mitochondria, binding of death ligand to its receptor or p53-
mediated gene expression, respectively. The release of pro-apoptotic
factors from the mitochondria (e.g. cytochrome c, IAP antagonists,
endo-DNAse) is a key event in apoptosis. The membrane pore can be
formed by pro-apoptotic multidomain members (Bax, Bak) of the Bcl-
2 protein family, which are normally restrained by the anti-apoptotic
multidomain members (e.g. Bcl-2, Bcl-XL) [111]. Pore formation and
thence apoptosis is promoted by the BH3-only members (e.g. Bad, Bid,
Bim, Puma, Noxa) of the Bcl-2 family, which are particulate pro-
apoptotic factors forwarding various triggers of apoptosis. Bad is kept
phosphorylated and inactive by PKB/Akt, and initiates pore formation
in the absence of survival signal. Bid is truncated and activated upon ex-
ogenous death signals through the death inducing signaling complex.
Induction of Bim is part of the ER stress response, while Puma and
Noxa are induced by p53 [111]. The complex control of apoptosis is af-
fected by ROS and by various reactive products of lipid peroxidation in
multiple ways. Here we are summarizing the major mechanisms, in
which HNE is involved directly; for a more comprehensive overview
of the topic see Dalleau et al. [112].
Oxidative stress affects caspase activation and function in multiple
ways. Although the maintenance of a certain antioxidant capacity is
required for appropriate proteolytic activity of caspases, moderate glu-
tathione depletion seems to play an important role in procaspase cleav-
age [113]. Two initiator (8 and 9) and the major effector (3) caspases
were found to be activated directly by glutathione depletion in HNE
treated human T-cell leukemia Jurkat cells. The underlying glutathione
depletion was due to oxidation by HNE rather than Fas-mediated gluta-
thione release across the plasma membrane [114]. HNE treatment
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of mitochondrial functions and induction of cytochrome P4502E1,
which led to an enhanced apoptosis in PC12 rat phaeochromocytoma
cells [115]. Stimulated expression of glutathione S-transferase A4-4, a
key enzyme of glutathione synthesis in these cells [115] can be consid-
ered as a defense mechanism since the protective effect of this enzyme
against HNE-induced apoptosis was revealed in human osteoarthritic
chondrocytes [116]. The role of glutathione depletion was further sup-
ported by the observation that PC12 cells can be protected from HNE-
induced cytotoxicity through an increased intracellular glutathione
level [117]. These ﬁndings do not reveal any direct interaction between
HNE and pro-caspase proteins, yet they strongly support the involve-
ment of cellular redox state-linked signaling pathways in HNE-
induced caspase activation. In line with this, activation of the stress ki-
nases JNK and p38MAPK and simultaneous down-regulation of ERK ac-
tivity were demonstrated to play a primary role in the HNE-dependent
apoptosis induction in 3 T3 mouse ﬁbroblasts [118]. The normal func-
tioning of the ER, especially the luminal oxidative folding is largely af-
fected by disturbances in the cellular redox state and it is connected to
glutathione homeostasis in particular [119,120]. It is therefore likely
that the ER stress also contributes to HNE-induced caspase activation.
Development of an ER stress in HNE-treated cells has been discussed
in relation to autophagy [48]. Several other studies support the ER
stressor action of HNE in various cell types [51,52] and it has also been
shown to be a link in HNE-induced, redox-mediated apoptosis [121].
In addition, the aggravation of the ER stress-induced cardiac dysfunc-
tion in ALDH2 knockout mice can be attributed to a similar mechanism
[122].
Interference of HNEwith the survival signal has been found in Jurkat
cells [123], in human osteoarthritic chondrocytes [116] and in MG63
human osteosarcoma cells [124]. A decrease in the amount of active
phosphorylated Akt, which leads to apoptosis induction thorough an in-
creased Bax and decreased Bcl-2 protein level, likely contributes to
HNE-induced cytotoxicity. However, Akt dephosphorylation and inacti-
vation was found to be caspase-3-dependent in HNE-treated Jurkat
cells, which contradicts its primary role and also strongly questions its
HNE speciﬁcity. It still might play a positive feedback role enhancing
theHNE-induced primary caspase activation. According to the proposed
mechanism, caspases down-regulate Src, and hence decrease the inhib-
itory Tyr-phophorylation of protein phosphatase 2A (PP2A), which in
turn dephosphorylates Akt for inactivation [123].
Activation of p53has beenmentioned as amechanism leading to cell
cycle arrest. This transcription factor is known to act as central guardian
of genomic integrity, and as such, it can also stimulate programmed cell
death after a severe damage. Accordingly, induction of p53 family gene
expression in HNE-treated SK-N-BE neuroblastoma cells not only hin-
dered proliferation but also increased the number of apoptotic cells
[104]. It should be noted, that p53 activation does not appear to be a
key factor in HNE-induced apoptosis. For example, the pro-apoptotic ef-
fect of HNE in RAW 264.7 murine macrophage cells has been shown to
be dependent on cytochrome c release but not p53 accumulation [125].
4. HNE in the pathogenesis of human diseases
Oxidative/electrophilic stress and increased lipid peroxidation are
important factors in the pathogenesis and progression of several
human diseases. Speciﬁcation of these pathologies has been the topic
of numerous excellent recent reviews [35,112,126]. Here we focus on
diseases of high incidence, inwhich the previously described alterations
in signaling and pathophysiology can be demonstrated.
4.1. HNE and myocardial diseases
Heart is the organ characterized by the highest oxygen uptake and
consumption in the body due to its constant pumping activity [127].
Its energy utilization mainly depends on oxidative phosphorylation bythe myocardial mitochondria. Accordingly, the human ventricular
myocyte contains about 7000 mitochondria, occupying approximately
25% of the cytoplasmic volume [128,129]. The high myocardial oxida-
tive capacity is a constant source of ROS generation and secondary
HNE production [130]. While free radicals are short lived, HNE can per-
sist and travel from the site of their origin [6]. Under normal conditions,
cardiacHNE is neutralized by aldehyde dehydrogenases (ALDHs), gluta-
thione S-transferases and aldose reductase [35,131]. However, various
pathologic conditions, such as myocardial ischemia reperfusion, heart
failure, doxorubicin toxicity and diabetes can overwhelm themetabolic
capacity leading to increased HNE formation and consequential
myocardial dysfunction [130].
Accordinglymyocardial HNE accumulation and toxicity has been im-
plicated in several cardiac diseases. It has been demonstrated that oxi-
dative stress is elevated in failing human myocardium [132]. HNE-
modiﬁed protein expressionwas5-fold elevated in patientswith dilated
cardiomyopathy compared to controls, and carvedilol, a beta-blocker
with intrinsic antioxidant capacity, reduced HNE levels by 40%, with
functional amelioration of heart failure symptoms [132]. Comparison
of 8 patients with chronic heart failure (CHF) with 8 age matched pa-
tients revealed that patients with CHF and low ejection fraction had sig-
niﬁcantly higher unsaturated aldehyde, including plasma HNE levels
when compared to healthy controls [133]. Total aldehyde concentration
was inversely correlated with +dP/dt left ventricular pressure rise, a
well-established indicator of global left ventricular contractility, and
cardiac output [133]. In a similar but larger scale study, the blood and
plasma levels of protein bound HNE products (HNE-P) were assessed
in 61 heart failure (HF) and 71 control patients [134]. All classes of cir-
culating fatty acids and potential HNE-P precursors n− 6 PUFAs, specif-
ically linoleic acid were also quantiﬁed. It was shown that while the
circulating levels of HNE-P were similar between heart failure and con-
trol patients, HF patients had signiﬁcantly decreased levels of HNE-P
precursor linoleic acid [134]. In addition, a strong association between
HNE-P, linoleic acid and HDL-cholesterol was found and it was sug-
gested that relative HNE-P increase is associated with HDL-cholesterol
decrease in HF patients. HNE-P levels in HF patients were found to pos-
itively correlate with New York Heart Association (NYHA) symptom
class level [134].
The role of HNEhas also been implicated inmyocardial ischemia and
reperfusion injury. This assumption was tested in isolated perfused
hearts from normotensive and spontaneously hypertensive rats with
cardiac hypertrophy and signs of heart failure, which were subjected
to 30 min global ischemia followed by another 30 min of reperfusion
[135]. Generation and release of HNE were demonstrated post-
ischemic reperfusion from myocardial efﬂuent in both animal groups.
In addition, maximum concentration of HNE in the perfusate correlated
with the highest incidence of ventricularﬁbrillation andmaximum con-
tractile dysfunction in spontaneously hypertensive rats animals [135].
The effect of ischemia reperfusion on myocardial HNE generation was
studied in a rat heart transplantation model [136]. Excised hearts were
ﬁrst subjected to 30, 240, 480 min of cold ischemia. Subsequently they
were transplanted into the recipient animal, connected to the abdomi-
nal aorta and vena cava and reperfused for 240 min. Immunohisto-
chemical staining revealed that cold ischemia did not increase
myocardial HNE protein adduct formation. In contrast, transplantation
and reperfusion markedly enhanced HNE protein adduct generation
by 6-fold, independent of preceding ischemic time [136]. Mitochondrial
isoform aldehyde dehydrogenase 2 (ALDH2) was recently identiﬁed as
an enzyme whose activation by phosphorylation reduced myocardial
infarct size by 60% in a rodent model of myocardial ischemia [137]. It
was postulated that ALDH2mediated cardioprotectionwas likelymedi-
ated by the elimination of cytotoxic aldehydes particularly HNE. Indeed,
pharmacologic activation of ALDH2 led to an in vitro 34% reduction of
HNE levels and 60% in vivo reduction in infarct size [137]. The effect of
both ALDH2 overexpression and knockout on myocardial ischemia
and HNE protein content was further investigated [81]. ALDH2
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prevented the decrease in left ventricular fractional shortening thus
left ventricular dysfunction following IR when compared to control an-
imals. In controls HNE protein adduct formation was signiﬁcantly in-
creased during ischemia and stayed elevated during reperfusion [81].
ALDH2 overexpression depressed HNE rise both during ischemia and
reperfusion, while ALDH2 knockout increased HNE protein adduct for-
mation during both circumstances. In vitro exogenous HNE treatment
signiﬁcantly compromised cardiomyocyte mechanical function, which
in turn was attenuated by ALDH2 overexpression, providing direct evi-
dence to HNE toxicity. The effects of chronic pharmacologic ALDH2 acti-
vation have been investigated recently in a post-infarction heart failure
rat model [138]. Male Wistar rats were subjected to myocardial infarc-
tion surgery via the ligation of left anterior descending artery. Heart
failure ensured approximately 4 weeks after coronary artery ligation,
at this time baseline myocardial parameters were determined, and ani-
malswere randomly assigned to chronic Alda-1 treatment, a pharmaco-
logic activator of ALDH2 enzyme. 6 weeks later the animals were
analyzed and sacriﬁced. Alda-1 treatment of HF animals signiﬁcantly
improved left ventricular ejection fraction and reversed pathological
ventricular remodeling of animal hearts. In the ALDH2 activated HF
animals HNE protein adduct levels decreased to sham operated control
animal levels [138]. From these experiments one can conclude, that
HNE accumulation plays a key role in the pathogenesis of bothmyocar-
dial ischemia reperfusion injury and heart failure, while its removal by
ALDH2 enzyme activation is a promising target for pharmaceutical
intervention.
4.2. HNE and cancer
Although the cytopathological effects of HNE have been discovered
more than three decades ago [2,139,140], the role of HNE during carci-
nogenesis and cancer progression is still debated.
Numerous HNE-induced DNA modiﬁcations were described, and
found to be potentially mutagenic [141–143]. The pathogenic role of
these DNA lesions is strongly supported by the observation that HNE-
DNA adducts are preferentially formed at the third base of codon 249
(−GAGGC/A-) in the most frequently mutated gene in human cancers,
the p53 [144]. Nevertheless, the greater reactivity of HNE to proteins
compared to DNA gave rise to the assumption that modulation of pro-
teins involved in DNA repair may contribute to the cytotoxic and carci-
nogenic effects of HNE. Indeed, HNE was shown to hinder nucleotide
excision repair of DNA damage induced by benzo[a]pyrene diol epoxide
(BPDE), as well as DNA damage induced by UV light irradiation in
human colon and lung epithelial cells [145]. These results strongly
suggest that HNE damages not only the DNA molecule itself but also
the DNA repair mechanisms and contributes to human carcinogenesis.
Initial studies found low level of HNE in tumor tissues compared
with healthy tissues, which was explained by rapid and efﬁcient oxida-
tive and conjugative pathways eliminating HNE metabolites from
tumor cells [146] and low rate of lipid peroxidation in hepatoma cells
[147]. Low levels of HNE were also associated with a decrease in the
synthesis and expression of the antiproliferative cytokine, transforming
growth factor beta1 (TGF-β1), which repression of TGFβ1 in turn has
been shown to correlate with an increase in carcinogenesis progression
in human malignant colon tumors [148,149]. Some recent studies have
reported controversial observations in several types of human cancers
[150–153]. Moreover, other results showed that HNE-protein adduct
formation might be implicated in different precarcinogenic stages of
hepatitis [154]. The discrepancy of these ﬁndings can be explained
with the heterogeneity of HNE formation and metabolism in various
tumor cells. Firstly, the membrane compositions showed different cho-
lesterol/polyunsaturated fatty acid ratios, which determine different
tendencies to HNE formation [155]. Secondly, certain tumor cells can re-
veal a higher expression of detoxiﬁcation enzymes and antioxidant pro-
teins allowing more efﬁcient and rapid HNE metabolism and excretion[156]. The α,β-unsaturated aldehydes produced as a result of cellular
membrane lipid peroxidation were found to have a dose-dependent
promoter activating effect on glutathione S-transferase, the key HNE-
metabolizing enzyme, in rat hepatoma cells [157].
As a cancer therapy, anticancer drugs and radiotherapy can induce
oxidative stress and trigger cancer cells to apoptosis, however some
cells escape the apoptosis through the adaptation to intrinsic oxidative
stress, which confers drug resistance. The central role of Nrf2 in themet-
abolic regulation in cancer cells were highlighted in recent studies [158,
159]. In malignant cells Nrf2 activation provides energetic adaptability
and growth advantage; hence increase cancer chemoresistance [160].
Since HNE has direct inﬂuence on Keap1–Nrf2–ARE pathway, future
studies will be necessary to distinguish physiologic and pathologic
roles of HNE, with particular attention to the pro-oxidant anticancer
agents and the drug-resistant mechanisms, which could be modulated
to obtain a better response to cancer therapy.
4.3. HNE and neurodegenerative diseases
The sensibility of a living tissue towards oxidative stress has been
greatly attributed to its susceptibility to lipid peroxidation, which in
turn largely depends on its PUFA levels. While low PUFA levels can pro-
vide an increased resistance towards oxidative stress, as in the case of
cancer cells, certain cell types including neurons possess PUFA-rich
membrane compartments containing high levels of the HNE-precursor
omega-6 fatty acids. Combined with the high abundance of metal ions
participating in redox transitions and intense oxygen consumption,
brain tissue becomes a prime subject of free radicals and HNE-related
degenerative disorders [161,162].
4.3.1. Huntington's disease
The genetic background of Huntington's disease is well deﬁned, and
aggregation of the polyglutamine containingmutant huntingtin protein
in the striatumand the cerebral cortex [163] has been extensively inves-
tigated. The disease manifests as a late onset neuromotor disorder that
has a decade long progress from increasing chorea-like involuntary
movements to the ﬁnal stage akinesia. In exploring the pathology of
Huntington's on the subcellular level, oxidative stress related scenarios
have been examined. The ﬁndings, in connection with energy metabo-
lism andmitochondrial dysfunction [164], oxidative damage in the cen-
tral nervous system [165] and in peripheral blood [166], pointed to
oxidative stress as a common denominator. Although the trigger has
yet to be found, oxidative damage is generally suggested to be an impor-
tant part of the pathophysiology of Huntington's disease. In a compre-
hensive review by Stack et al., several oxidative modiﬁcations of
proteins and DNA were identiﬁed, and even preventive antioxidant
Q10 and creatine treatment was proposed [167]. Evidence of lipid per-
oxidation was also found in Huntington's brain tissue in the form of el-
evatedMDA and HNE levels. Furthermore, HNE was found to colocalize
with huntingtin inclusions [168]. Inhibition of proteasomal function by
HNE-dependent modiﬁcations [169] can lead to accelerated accumula-
tion of aggregates. Protein degradation machinery plays an essential
role in eliminating folding incompetent proteins. It has also been
suggested that the decrease in superoxide dismutase levels and the
altered energy metabolism found in Huntington's effected tissue
samples can indirectly effect lipid peroxidation and HNE abundance
[170].
4.3.2. Parkinson's disease
Most commonly known for the symptoms bradykinesia and resting
tremors (shaking palsy), Parkinson's disease (PD) is the second most
abundant neurodegenerative disease. PD presents with the occurrence
of Lewy bodies found in the putamen and substantia nigra of the brain
as the histological hallmarks of the disease. A major component of
Lewy bodies is themitochondrial and synaptic vesicle formation related
protein:α-synuclein (α-syn). Oxidation andnitration ofα-synhas been
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modiﬁcations by ROS also impair the autophagic machinery, resulting
in decreased α-syn degradation [172]. Lipid peroxidation also leads to
the emergence of α-syn derivatives. HNE-α-syn has a greatly increased
oligomerization potential; consequently this adduct formation is
suspected to serve as a trigger for aggregation [171]. The involvement
of this process in the pathological progress was fortiﬁed by the ﬁnding
that Lewy bodies stain positive for HNE [173,174]. It has been reported
that different electrophiles can initiate the formation ofα-synoligomers
with distinct biochemical, morphological and functional proper-
ties [175]. It can be supposed that different oligomers affect the
autophagic machinery differently. HNE promotes the formation of
seeding-capable oligomers, which distinguished themselves by a
cell-to-cell transfer ability [176].
Besides the direct α-syn relation, HNE was also found in connection
with dopamine transport. The binding to the dopamine transporter and
inhibiting dopamine uptake further contributes to the loss of dopamine
dependent and dopamine secreting neurons [170,177], resulting in
further progression of PD.4.3.3. Alzheimer's disease
Alzheimer's disease (AD) is the most common andmost extensively
studied neurodegenerative disorder with about 1000 studies published
annually. The relatedmental pathology frommild cognitive impairment
(MCI) to severe late stage Alzheimer's disease is being described in in-
creasing details. At the cellular level, the pathomechanism of AD is at-
tributed to the impaired processing of amyloid precursor protein by
gamma secretases leading to the accumulation of aggregation prone
and ROS generating amyloid beta (aβ) peptide. The broad range of stud-
ies approach Alzheimer's as a conformational disease [178], a neuro-
transmission disorder [179], a response to inﬂammatory signals [180],
and even a metabolic syndrome [181].
Increasing evidence has been collected by various groups demon-
strating that besides – and in connection with – the well-known senile
plaque pathology, increased oxidative stress is common in the central
nervous system in patients with AD [182,183]. Since early in vitro stud-
ies conﬁrmed the production of hydrogen peroxide and lipid peroxide
by increased aβ levels [184], the presence of various lipid peroxidation
products has been reported including MDA, F2-isoprostanes [182,185]
and HNE [186]. For the last two decades, studies have conﬁrmed the el-
evated HNE levels in AD, both in animal models [187] and in patients
[188,189]. HNE has been shown to be amember of the amyloid cascade,
and contributes to AD pathology as an effector for aβ-induced free
radicals [190–192]. The subsequent oxidative modiﬁcations affect a
wide variety of proteins leading to structural and functional alterations
in AD, both at the intracellular and synaptic membrane level [193,194],
including enzymes involved in the elimination of aβ itself that can even
lead to a disease spiral phenomenon [195]. Proteomic analysis of late
stage AD samples has shown that while HNE can directly affect inter-
neuronal communication via the modiﬁcation of key proteins such as
collapsin response mediator protein 2 [194] and glial glutamate trans-
porter (GLT-1) [196], its targets are often key enzymes of energymetab-
olism: aconitase, aldolase, enolase, and ATP synthase [197], as well as
enzymes involved in antioxidant defense: peroxiredoxins, superoxide
dismutase, and heme oxygenase [162]. Corollary to the dysfunction of
these enzymes, the defenses of neuronal tissue against oxidative
damage are further weakened as a result of HNE.
Besides the protein modiﬁcations, another reported scenario of HNE
causing impaired energymetabolism in AD is dihydrolipoic acid (DHLA)
consumption via direct adduct formation. In HNE treated brain tissue,
both the overall level and enzymatic activity of lipoamide dehydroge-
nase (LADH) was found to be decreased as a result of ROS/HNE modiﬁ-
cations that led to diminished DHLA production. The combined effect of
decreased DHLA synthesis and HNE-lipoic acid conjugate formation
leads to a depleted ATP pool [189].Due to its multiple targets and undeniable effects, lipid peroxidation
and HNE adduct formation should attract increased attention and lead
to further investigations in the ﬁeld of neurodegenerative disorders.
5. Concluding remarks
HNE emerged 34 years ago as a deleterious, cytotoxic product
of lipid peroxidation. During the time elapsed countless pathological
effects have been attributed to HNE toxicity. However, the intensive
research in the ﬁeld also revealed less destructive and more speciﬁc
effects of themolecule. Recent observations on the role of HNE in signal-
ing have shed light on adaptive cytoprotective responses too. It became
evident that activation of HNE sensors prepare the cells for antioxidant
defense, stimulate the elimination of damaged cellular components or
even serve the protection of the organism by inducing apoptosis in
severely injured cells [112,198]. Although excessive HNE formation
is obviously a pathogenic factor, activation of these protective mech-
anisms deserves a great scientiﬁc interest because it might reveal
newmolecular targets of medical signiﬁcance [36,199]. Further stud-
ies on HNEmetabolism and signaling can contribute to the better un-
derstanding of cardiovascular and neurodegenerative diseases.
Moreover, HNE research can largely promote the development of
new medical interventions, e.g. the exploration and improvement
of electrophile therapeutics.
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